WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 PM ET.
A live webcast of the presentation will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.
Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718
Media Contact
Tom Donovan, Ten Bridge Communications
tom@tenbridgecommunications.com
857.559.3397
KENNEWICK, Wash. and HOUSTON, Dec. 11, 2025 /PRNewswire/ -- Cadwell, a global leader in neurodiagnostic…
New embedded solution empowers more than 900,000 small businesses to offer flexible, affordable health coverage directly…
CONSHOHOCKEN, Pa., Dec. 11, 2025 /PRNewswire/ -- Suvoda, a global clinical trial technology company, today announced…
TraceLink announced its support for UNICEF's Traceability and Verification System (TRVST), a global initiative improving…
VISALIA, Calif., Dec. 11, 2025 /PRNewswire/ -- Maison Law Accident & Injury Lawyers announces the…
NASHVILLE, Tenn., Dec. 11, 2025 /PRNewswire/ -- The Tennessee Department of Correction (TDOC) has expanded its…